Nuclear medicine procedures in lung cancer

Although radiography, computed tomography and magnetic resonance imaging ar e still the methods of choice for the study Of lung cancer, they have certa in limitations in the determination of the nature of suspicious lung nodule s, the evaluation of mediastinal involvement, the assessment of the viabili ty of previously treated lesions and the diagnosis of tumour relapse. There is a wide range of current oncological requirements related to lung cancer : detection of malignant lesions at the earliest stage and in the most effe ctive way; the definition of the biological characteristics of a lesion (pr oliferation, aggressiveness, differentiation, etc.); the need to define the operability of the patient (function of residual lung and staging); and th e need to evaluate the behaviour of the tumour (response to therapy, early detection of recurrences, metastatic spread). Most of the efforts of the nu clear medicine community have been focussed on diagnosis, staging, restagin g and therapy monitoring of lung cancer. Many radiopharmaceuticals have bee n employed for this, including gallium, monoclonal antibodies, somatostatin analogues, lipophilic cations and positron emission tracers. There is ampl e evidence that nuclear medicine techniques may provide complementary infor mation with respect to anatomical imaging, for example in the assessment of preoperative function by means of ventilation and perfusion scintigraphy, or in tumour localisation by means of specific tumour-seeking agents. Howev er, clinical data suggest that, when properly used, nuclear medicine proced ures in some cases may be not only complementary to radiology but essential fur the clinical management of lung cancer. An example of such a procedure is fluorodeoxyglucose positron emission tomography (FDG PET) the introduct ion of which has greatly contributed to confirmation of the clinical value of nuclear medicine in this field. FDG PET has proved of great help in lung cancer management and its cost-effectiveness in lung cancer staging is fir mly established. In this review the results of the most important nuclear m edicine techniques are summarised and their value in clinical practice is d iscussed. General, updated information is provided about the epidemiology, biology and clinical management of lung cancer, and about the role of nucle ar medicine in these areas.